Forecast

Buy	18
Hold	4
Sell	3

News Go to news feed

Novo Nordisk taps Anthropic AI Claude to speed up drug development

Novo Nordisk has entered a partnership with Anthropic and will test the AI model Claude, including Claude Science, to address scientific questions in the drug discovery process and advance AI-driven software development. The collaboration aims to develop targeted solutions and workflows to accelerate drug research; AI will be used under human supervision. Novo shares in Copenhagen fell about 0.2% at one point, trading at 275.35 DKK. » More on finanzen.net
Novo Nordisk faces mid-term rebound but long-term caution after revenue downgrades

Novo Nordisk is expected to see a short-term stock price recovery following a significant decline and two downward revenue revisions, but analysts urge caution due to reduced growth expectations and lower free cash flow forecasts. The company's valuation appears less attractive despite a lower P/E ratio, as its market cap remains high relative to earnings. Technical analysis suggests a temporary bounce, but further selling pressure may resume in the longer term. » More on investing.com
Novo Nordisk downgraded to 'neutral' by UBS due to uncertain outlook

UBS has downgraded Novo Nordisk from 'buy' to 'neutral' and significantly lowered its price target. The bank sees major challenges ahead for the Danish pharmaceutical company, particularly regarding its weight loss drugs Wegovy and Ozempic. The outlook for the company's cash flow is also considered uncertain. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2002, Novo Nordisk 'B' has already paid €0.76 in dividends. The last payout was in March 2002.

Financials

In the last year, Novo Nordisk 'B' had revenue of €232.26bn and net profit of €83.68bn

(EUR)	2023	YoY
Revenue	232.26bn	31.26%
Gross profit	196.5bn	32.32%
Net profit	83.68bn	50.71%
EBITDA	114.63bn	50.01%

Fundamentals

Metric	Value
Market capitalization	€406.69bn
Number of shares	4.45bn
52-week high/low	€185.12 - €51.65
Dividends	No
Beta	0.24
P/E ratio	10.73
PEG ratio	2.14
P/B ratio	5.63
P/S ratio	3.79

Company profile

Novo Nordisk A/S ist ein Gesundheitsunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten befasst. Das Unternehmen ist auch in der Entdeckung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten tätig. Das Unternehmen ist in zwei Geschäftsbereichen tätig: Diabetes- und Adipositasbehandlung und Biopharmazeutika. Das Segment Diabetes und Adipositas umfasst Insulin, GLP-1, andere proteinbezogene Produkte wie Glucagon, proteinbezogene Verabreichungssysteme und Nadeln sowie orale Antidiabetika. Das Biopharmaziesegment des Unternehmens umfasst die Therapiebereiche Hämophiliebehandlung, Wachstumshormontherapie und Hormonersatztherapie. Das Unternehmen bietet auch das Produkt Saxenda zur Behandlung von Fettleibigkeit an. Das Unternehmen bietet eine Reihe von Produkten an, darunter NovoLog/NovoRapid, NovoLog Mix/NovoMix, Prandin/NovoNorm, NovoSeven, Norditropin und Vagifem. Zum 31. Dezember 2016 vermarktete das Unternehmen seine Produkte in über 180 Ländern. Die regionale Struktur des Unternehmens besteht aus zwei Geschäftseinheiten: Nordamerika und International Operations.

Name	Novo Nordisk 'B'
CEO	Lars Fruergaard Jorgensen
Headquarters	Bagsvaerd, Denmark
Website	novonordisk.com/investors/investor-highlights.html
Sector	Health Care
Industry	Pharmaceuticals
IPO	07/06/2001
Employees	59,337